Sacubitril/valsartan has an underestimated impact on the right ventricle in patients with sleep-disordered breathing, especially central sleep apnoea syndrome - 14/06/24
Highlights |
• | Sacubitril/valsartan (S/V) is a key treatment for heart failure. |
• | Sleep-disordered breathing (SDB; obstructive and central) is a common co-morbidity. |
• | SDB has an impact on the prognosis of patients with heart failure. |
• | After only 3 months of treatment, S/V improved LV and RV function. |
• | This was achieved via a significant increase in TAPSE and a reduction in sPAP. |
• | The improvement in RV function was most evident in patients with central SDB. |
• | To date, those with central SDB cannot benefit from any treatment other than drugs. |
Abstract |
Background |
Sacubitril/valsartan has been demonstrated to significantly improve left ventricular performance and remodelling in patients with heart failure. However, its effects on the right ventricle in patients with chronic heart failure and sleep-disordered breathing (SDB) have not been studied.
Aim |
To investigate the impact of sacubitril/valsartan treatment on right ventricular function in patients with SDB.
Methods |
This was a subanalysis of an observational prospective multicentre study involving 101 patients. At inclusion, patients were evaluated by echocardiography and nocturnal ventilatory polygraphy, which allowed patients to be divided into three groups: “central-SDB”; “obstructive-SDB”; and “no-SDB”.
Results |
After 3 months of sacubitril/valsartan therapy, a positive impact on right ventricular function was observed. In the general population, tricuspid annular plane systolic excursion increased by +1.32±4.74mm (P=0.024) and systolic pulmonary artery pressure decreased by −3.1±10.91mmHg (P=0.048). The central-SDB group experienced the greatest echocardiographic improvement, with a significant increase in tricuspid annular plane systolic excursion of +2.1±4.9mm (P=0.045) and a significant reduction in systolic pulmonary artery pressure of −8.4±9.7mmHg (P=0.001).
Conclusions |
Sacubitril/valsartan improved right ventricular function in patients with heart failure and SDB after only 3 months of treatment. The greatest improvement in right ventricular function was observed in the central-SDB group.
Le texte complet de cet article est disponible en PDF.Keywords : Heart failure, Sacubitril/valsartan, Sleep apnoea syndrome, Right ventricular function, Nocturnal ventilatory polygraphy
Plan
| ☆ | Tweet: sacubitril/valsartan improved right ventricular function in patients with heart failure and sleep disordered breathing after only 3 months of treatment. The greatest improvement in right ventricular function was observed in the central-SDB group. |
Vol 117 - N° 6-7
P. 409-416 - juin 2024 Retour au numéro
Article précédent
- Evaluation of new predictive scores for sudden cardiac death in childhood hypertrophic cardiomyopathy in a French cohort
- Pierre-Alexandre Fontanges, Christelle Marquie, Ali Houeijeh, Jean-Benoît Baudelet, Adélaïde Richard, Christian Amenyah, Sophie Lucidarme, Mathilde Bonnet, Alexandre Delarue, Saïd Bichali, Nala Abou Assi, Sylvestre Marechaux, Aymeric Menet, Guy Vaksmann, François Godart, Olivia Domanski
- Rationale and design of the FRENch CoHort of myocardial Infarction Evaluation (FRENCHIE) study
- Alexandre Gautier, Nicolas Danchin, Gregory Ducrocq, Alexandra Rousseau, Yves Cottin, Guillaume Cayla, Fabrice Prunier, Isabelle Durand-Zaleski, Philippe Ravaud, Denis Angoulvant, Pierre Coste, Gilles Lemesle, Claire Bouleti, Batric Popovic, Emile Ferrari, Johanne Silvain, Olivier Dubreuil, Thibault Lhermusier, Pascal Goube, François Schiele, Gérald Vanzetto, Victor Aboyans, Romain Gallet, Hélène Eltchaninoff, Christophe Thuaire, Jean-Guillaume Dillinger, Franck Paganelli, Julie Gourmelen, Philippe Gabriel Steg, Tabassome Simon, on behalf of the FRENCHIE investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?